$QNTM News

Quantum BioPharma Momentum Score Surges As Investors Cheer Progress In MS Research

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

Quantum Biopharma shares are trading higher after the company announced it signed a binding LOI with Allucent, a global contract research organization experienced in supporting central nervous system clinical trials, to support the planned Phase 2 clinical trial of Lucid-MS for the treatment of multiple sclerosis.

Quantum Biopharma shares are trading higher after the company announced it signed a binding LOI with Allucent, a global contract research organization experienced in supporting central nervous system clinical trials, to support the planned Phase 2 clinical trial of Lucid-MS for the treatment of multiple sclerosis.

Quantum Biopharma Provides Corporate Update

Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status

Quantum BioPharma Q4 EPS $(0.71) Beats $(0.93) Estimate

Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

Quantum Biopharma Appoints Dr. Salvatore Napoli As Principal Investigator For Phase 2 Clinical Trial Of Lucid-21-302 For Treatment Of Demyelination In Multiple Sclerosis

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Quantum BioPharma Publishes Data From Clinical Study Of NCT06505239 Of Its Dietary Supplement Product Unbuzzd To Evaluate Impacts Of Unbuzzd On Alcohol Intoxication, Alcohol Metabolism

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

Reported On March 11: Quantum BioPharma Provides Corporate Update; Announces That Further To Its News Release On March 10, 2026, The Company Has Revised The Terms Of The Debenture Units; Reduce The Conversion Price Per Share To $3.00; Increase The Number Of Warrants Included As Part Of Each Debenture Unit To 333.33; Reduce The Exercise Price Per Warrant Share To $3.75

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares